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Background. Dyspnea is one of the main complaints in a group of COPD patients due to exposure to sulfur mustard (SM) and is
refractory to conventional therapies. We designed this study to evaluate eﬀectiveness of nebulized morphine in such patients.
Materials and Methods.Inadouble-blindclinicaltrialstudy,40patientswithdocumentedhistoryofexposuretoSMwereallocated
totwogroups:group1whoreceived1mgmorphinesulfatedilutedby4ccnormalsaline0.5%usingnebulizeroncedailyfor5days
and group 2 serving as control who received normal saline as placebo. They were visited by pulmonologist 7 times per day to check
symptoms and signs and adverse events. Diﬀerent parameters including patient-scored peak expiratory ﬂow using pick ﬂow meter,
visual analogue scale (VAS) for dyspnea, global quality of life and cough, and number of respiratory rate, night time awaking for
dyspnea and cough have been assessed. Results. The scores of VAS for dyspnea, cough and quality of life and also respiratory rate,
heart rate, and night time awaking due to dyspnea and night time awaking due to cough improved signiﬁcantly after morphine
nebulizationwithoutanymajoradverseevents.Alsopickexpiratoryﬂowhasbeenimprovedsigniﬁcantlyafternebulizationineach
day. Conclusion. Our results showed the clinical beneﬁt of nebulized morphine on respiratory complaints of patients due to ex-
posure to SM without signiﬁcant side eﬀects.
1.Introduction
Dyspnea is the most common complaint in patients with
chronic obstructive pulmonary disease (COPD) [1]. As the
disease progresses to severe COPD, dyspnea may often dec-
rease quality of life and activities of daily living. Opioids have
been utilized to suppress the sensation of dyspnea in the pa-
tient with chronic and progressive COPD as palliative ther-
apy [2]. Systemic treatment with opioids has been reported
to reduce dyspnea in some patients groups [3, 4], but adverse
eﬀects are common and limit their long-term use. Nebulized
morphine is potentially attractive, since fewer side eﬀects
have been noted with inhaled morphine compared with
injectableroutes, and some controlledstudies have suggested
ab e n e ﬁ c i a le ﬀect on dyspnea [5–7]. This would oﬀer an
advantage if the relief of dyspnea could be relieved without
considerable adverse eﬀects [8].
In the patient with end-stage COPD, nebulized opioids
may be considered as a potential treatment option [8]. Mor-
phine may also decrease anxiety and diminish ventilatory
response to hypoxia and hypercapnia [9]. Eaton and asso-
ciates postulated that the mechanism of nebulized opioids
in patients with lung disease, although not well understood,
may be multifactorial. Depression of local opioid receptors
in the lungs, spinal cord and central respiratory centers, and
other systemic eﬀects may all have a role [8, 10].
However, the evidences in the literature are still contro-
versial and placebo-controlled studies to support nebulized2 Pulmonary Medicine
morphine for the relief of dyspnea in patients with COPD
are not suﬃcient [8].
Dyspnea is one of the main complaints in a group of
COPD patients due to exposure to sulfur mustard (SM).
Bronchiolitis obliterans (BO) is the main underlying long-
term respiratory consequence in these patients [11, 12]. SM
is one of the major potent chemical warfare agents. Unfor-
tunately,IraqisusedsulfurmustardextremelyagainstIranian
population during Iraq-Iran war in (1984–1988). As a result
over the time about 100,000 Iranians were exposed to che-
mical warfare agents [13], and more than 30,000 survivals
still suﬀer from respiratory complications [14]. The study
was designed because of some reports asserting that inhaled
opioids are able to relieve severe dyspnea from malignant or
nonmalignantlungdisease[5,6].Consequently,wedesigned
this study for the ﬁrst time to evaluate eﬀectiveness of
nebulized morphine in this group of patients comparing to
the placebo group.
2.MaterialsandMethods
In a double-blind clinical trial study, 40 male patients with
COPD due to exposure to SM were enrolled. Patients with
history or abnormal laboratory tests indicating renal failure
or cardiovascular diseases and history of adverse reaction to
morphine were excluded.
T h e yw e r ea l l o c a t e dt ot w og r o u p s .G r o u p s1w h or e -
ceivedmorphinesulfateasinhalerandgroup2servedascon-
trol who received placebo. In morphine group, patients con-
sumed 1mg morphine diluted by 4cc normal saline 0.5%
using nebulizer once daily for 5 days. The placebo group
followed same instruction with just 5cc normal saline 0.5%.
They were visited by pulmonologist 7 times per day to check
symptoms and signs and adverse events.
The physician and patients were kept blind about the
consumed medication. We used PARI LC SPRINT nebulizer
with same type and color in two groups. It is a nebulizer that
cantransportmicro-aerocellwith2-3micronsindiameterto
lower airways such bronchiole in adults. In assessing the
potentialbeneﬁtofinhaledmorphineondyspneaandrelated
complaints in our patients, diﬀerent parameters such as peak
expiratory ﬂow using pick ﬂow meter, patient-scored visual
analogue scale (VAS) for dyspnea (ranged from 0, that is,
no dyspnea to 10, that is, worse dyspnea), cough (10-cm
linear scale on which patients indicate the severity of their
cough; 0mm represents no cough and 10cm the worst
cough ever) were assessed. In addition, number of respira-
tory rate, night time awaking for dyspnea, and cough has
been evaluated. Global quality of life was measured with a
VAS: a horizontal line of 10cm ranging from 0 (worst ima-
ginable quality of life) to 10 (perfect quality of life). The
study was performed according to the principles of the Dec-
laration of Helsinki. Informed consent was obtained from all
participating patients.
Statistical analysis was performed using SPSS version
16.0software(SPSSInc,Chicago,IL).Thet-testandrepeated
measured analysis were used to compare data between and
within groups. Values were presented as mean ± SD. A P
value less than 0.05 was considered signiﬁcant.
3. Results
Comparison of dyspnea, cough, and quality of life in two
groups has been shown in Table 1. There were statistically
signiﬁcantdiﬀerencesbetweenthemorphineandtheplacebo
group in VAS scores for dyspnea, cough, and quality of life.
Also there was signiﬁcant diﬀerence between two groups
regarding mean diﬀerence of night time awaking due to
dyspnea and night time awaking due to cough. Table 2 shows
mean of diﬀerences in respiratory rate, hear rate, night time
awaking for dyspnea, and cough in two groups.
Resultsof5-daymeanpickﬂowmeteroftwogroupsover
the time at 15th min, 30th min, 45thmin, 1sth, 2ndh, 4thh,
and 8thh after inhalation in each day are summarized in
Table 3. P value for comparison of two groups is based on
repeated measured analysis.
4. Discussion
The VAS scores for dyspnea, cough, and quality of life, and
number of respiratory rate, heart rate, night time awaking
due to dyspnea and night time awaking due to cough impro-
ved signiﬁcantly after morphine nebulization without any
major adverse events. Also pick expiratory ﬂow rate has been
improved signiﬁcantly after nebulization in each day com-
paring to placebo. No considerable adverse reactions oc-
curred in our study.
We used the VAS for evaluation of dyspnea in our series.
The sensitivity of the VAS is enough to detect changes in
breathlessness. Although, the Borg scale has greater reprodu-
cibility and is now widely used, the VAS has greater precision
and sensitivity [15]. The speciﬁcity of the Borg scale depends
ontheinstructionsgiventothesubject[15,16].Furthermore
we assessed global quality of life using VAS. The VAS is an
instrument with good validity, excellent reliability, moderate
distribution-based responsiveness, and good anchor-based
responsiveness compared to multiitem questionnaires. Its
use is recommended in clinical trials to assess global quality
of life [17].
Opioids have been administered through a variety of
routes to relieve dyspnea in patients with advanced COPD
since the late 19th century. Morphine also was administered
by inhalation to relieve dyspnea with least side eﬀects that
mighthaveoccurredwhenusedviasystemicroutes[16].The
mechanisms of action of nebulized opioids are not clear.
They may reduce the sensation of breathlessness primarily
through a central eﬀect on the brain. Also, it has been shown
that low doses of morphine consumed directly to the lung
via nebulizer are eﬀective in some patients. Three main
opioid receptors have been identiﬁed in the respiratory tract:
μ (MOR), δ (DOR), and k (KOR), which mediate the
eﬀects of the 3 primary families of endogenous opioids
(endorphins, enkephalins, and dynorphins, resp.) as well as
exogenous opioids such as morphine and codeine [18]. In
addition, the lungs also may contain a novel opioid receptor
[19, 20]. Among them the k receptor is the predominant
opioid receptor in the lung [21]. An additional suggested
mechanism for the therapeutic eﬀects of inhaled morphine
mightbetheinhibitionofpulmonary-irritantreceptors[22].Pulmonary Medicine 3
Table 1: Comparison of dyspnea, cough, and quality of life within and between two groups.
Group Before Day 1 Day 2 Day 3 Day 4 Day 5 P value
Dyspnea Morphine 6.9 ±1.16 .1 ±1.15 .7 ±0.95 .3 ± 1.05 .2 ±1.15 .1 ±1.0 <0.001
Placebo 7.1 ±1.57 .4 ±1.57 .3 ±1.57 .2 ± 1.47 .2 ±1.47 .2 ±1.4
Cough Morphine 5.8 ±1.85 .0 ±1.84 .6 ±1.64 .2 ± 1.74 .1 ±1.84 .1 ±1.7 <0.001
Placebo 5.5 ±1.95 .6 ±1.95 .5 ±1.95 .5 ± 1.95 .5 ±1.95 .5 ±1.9
Quality of
life
Morphine 4.5 ±1.34 .7 ±1.14 .7 ±1.74 .7 ± 1.74 .8 ±1.15 .0 ±1.2 0.03
Placebo 3.4 ±1.53 .4 ±1.43 .5 ±1.53 .5 ± 1.53 .5 ±1.53 .5 ±1.5
Table 2: Mean of diﬀerences in respiratory rate, hear rate, night
time awaking for dyspnea, and cough in two groups.
Morphine Placebo P value
Respiratory rate 1.5 ±1.10 .1 ±0.3 <0.001
Heart rate 1.7 ±1.60 .45 ±0.6 0.004
Night time awaking for dyspnea 1.0 ±0.60 .5 ±0.6 <0.001
Night time awaking for cough 1.2 ±0.70 .5 ±0.2 <0.001
Opioids depress the release of proinﬂammatory “substance
P,” which may help to decrease local inﬂammation [18]. We
also suppose the possible role of opioid to act on neurogenic
inﬂammation process as another involved mechanism for
palliation of respiratory symptoms. Therapeutic aerosols
have a wide range of particle sizes and shapes. It was con-
cluded that in particle size of 2.3 to 3μm, a solution of mor-
phine was more likely to place in the peripheral airways
during tidal breathing than particle size in 4.9μm, which
tends to cause impaction in the central airways [23]. In our
study a nebulizer that delivers a small particle size (mass
median diameter 3μm) was used for reaching better to bron-
chioles where there is location of main pathology of BO.
The eﬀect of nebulized morphine on dyspnea has been
remainedcontroversialuntilnowanddiﬀerentstudiesrepor-
ted mixed results [8]. Most studies using doses of 1–25mg
havenotshownconsiderablebeneﬁtfrominhaledopioidson
dyspnea [24–32], but other ones showed a beneﬁcial eﬀect
[33, 34]. Young et al. reported an increase in exercise endu-
rance in COPD patients after a low 5mg dose of nebulized
morphine [35]. In a small trial, a single dose of morphine-
6-glucuronide was administered to nine breathless patients
with cancer at dose levels of 5mg, 10mg, and 20mg. All pa-
tients reported improvement in dyspnea by VAS and Borg
scale with no apparent diﬀerences among doses [36, 37]. In a
studyof18patientswithCOPD,Satoetal.demonstratedthat
4mg nebulized morphine-6-glucuronide increased exercise
endurance [28]. Also, there have been several reports con-
cerning the eﬀectiveness of nebulized morphine in relieving
cancer-related dyspnea [5, 9, 38].
On the other hand, there are some studies against eﬀec-
tiveness of morphine in respiratory complaints. Foral and
colleagues reviewed seven studies on patients with a variety
of cardiorespiratory disorders who received nebulized mor-
phine. In ﬁve of studies on COPD, one study evaluated a
mix of pulmonary and nonpulmonary patients, and another
study was as a small cohort of patients with interstitial lung
disease (ILD). The authors concluded that the evidence did
not support the use of nebulized morphine for the relief of
dyspnea or in the improvement of exercise tolerance in pa-
tientswithCOPDorILD.Theyrecognizedthatdiﬀerencesin
dose, administration schedule, and inconsistent use of oxy-
genandbronchodilators couldhavecontributedtothevaria-
bility in results. However, reported side eﬀects were few
and mild. Furthermore, it was suggested that the underlying
disease for which the aerosol is delivered may inﬂuence the
deposition of particles [16].
In our study patients were not on oxygen therapy and all
werereceivelong-actingbronchodilatortwiceperdayduring
the5-daystudyperiod.Ourresultshoweddesirableeﬀective-
ness of once daily low dose nebulized morphine on dyspnea
andrelatedconsequencesinSMexposedBO.Itisveryintere-
sting because most trials have investigated the eﬀects of aero-
solized opioids on dyspnea and exercise tolerance in patients
with stable chronic cardiopulmonary disease and found no
eﬀect [39]. However, some point should be noted in this
setting. There is no evidence of emphysema as a consequence
of disrupted lung parenchyma in our patients [11]. Further-
more, they have not had other risk factors that are seen in
commoncasesofCOPDandBO.Theseshouldbeconsidered
as appreciate reasons for eﬀectiveness of nebulized opioid in
oursetting.Ofnote,thereisanirreversibleairﬂowlimitation
in such chemical injured that has not respond to routine
therapies.
Although, insuﬃcient well-designed studies are one of
the most important reasons for reluctance to prescription of
opioids, there are other limitations as well. They include fear
of respiratory depression and addiction in both physicians
and patients groups [40, 41]. There was no signiﬁcant in-
creasing in adverse eﬀects in most studies on nebulized mor-
phine. Also, the long-term prescription of opioid as a pallia-
tivetherapyforrespiratorysymptomsmayleadtotemporary
physicaldependencethatshouldnotbeconfusedwithaddic-
tion [42]. However, nebulization has a number of advan-
tages. First, nebulized opiates may be better tolerated at
higher doses than systemic administration. It may be devoid
of serious side eﬀects because its bioavailability is very small
[43]. Second, relief is likely to be more rapid than by oral
intake. Relief of dyspnea has been reported to occur shortly
after or within 10–15min of application of nebulization
treatment [40]. Third, patients can manage their dyspnea
by themselves easily, when dyspnea occurs or worsens.4 Pulmonary Medicine
Table 3: Pick ﬂow meter over the time in total 5 days after inhalation in two groups.
Baseline 15min 30min 45min 1h 2h 4h 8h P value
Morphine 66.7±20.48 4 .75 ±48.6 104.75 ±53.59 7 .7 ±52.79 6 .25 ±49.68 9 .2 ±51.48 9 .0 ±51.68 4 .2 ±47.6 0.017
Placebo 56.7±23.16 3 .2 ±21.97 5 .0 ±12.77 3 .5 ±12.86 4 .7 ±26.07 1 .0 ±16.16 8 .5 ±19.16 7 .1 ±18.2
These advantages suggest the possibility of the use of neb-
ulized morphine for patients at home as a rescue treatment
during dyspnea attack or prophylactically before daily activi-
ties [44].
It appears that nebulized opium beneﬁt lasts for a few
hours and an increase in the dose up to 80mg and in frequ-
encyuptoevery2histolerable[29].Interestingly,ourresults
revealedthatitsbeneﬁtremainedupto8hours.Inthisstudy,
nebulized doses of morphine lower than those previously
reported were administered. The eﬀect of nebulized mor-
phine is unlikely to be caused by systemic absorption of the
nebulized dose. Some reasons for this fact are as follows.
The bioavailability of nebulized morphine has been reported
5.5%(range5–35%)giventhatmuchofthedrugisdeposited
in the delivery systems [45–47], but systemic doses required
aﬀecting dyspnea range from 5 to 50mg. Furthermore, the
mean delay to obtain a peak serum concentration following
nebulization is 45min [45]. The maximum serum morphine
concentration was achieved by 45min and was approxi-
mately6timeslowerthanwithintramuscularadministration
[39]. We found that least dose, that is, 1mg nebulized mor-
phine shows its eﬀect on dyspnea just after 15min; the time
before a peak serum concentration supports central pul-
monary mechanism of action rather than systemic eﬀects.Of
note in cancer patients who suﬀer from intractable dyspnea,
relatively small amounts of inhaled opioids appear to im-
prove breathing comfort, despite the fact that these patients
alreadyarereceivinghighlevelsofparenteralopioidsforpain
management [5, 9, 29, 39, 44, 48].
This study has some limitations. The plasma concentra-
tions of morphine have not been measured. Also the time of
followup was not suﬃcient. Assessment of severity using
spirometrywasnotfeasible,thuswecouldnotmeasurevolu-
mes and just ﬂow was measured. Although ﬂow is dependent
to volume, it could be inﬂuenced by other variables like res-
piratory muscles work. Its eﬀective use in clinical practice
needs further examination. How long its eﬀectiveness sus-
tains,howmanytimesitcanbeusedsafely,andwhatthelim-
iting factor of this treatment is are very important remaining
questions. However, practical prescription of nebulized mor-
phine in this ﬁeld needs more evaluation with larger sample
sizeandlongerfollowsupperiod.Complementarystudywith
crossover method is appreciated.
5. Conclusion
Our study on COPD patients resulting from SM exposure
revealed that nebulized morphine is eﬀective for reducing
dyspnea and related complaints and can be used safely in
parallel with current therapies in this setting.
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